Macromolecular Imaging of White and Gray Matter Pathology in Multiple Sclerosis

Multiple Sclerosis Clinical Trial

Official title: Macromolecular Imaging of White and Gray Matter Pathology in Multiple Sclerosis

Status Enrolling by invitation

Clinical Trial Summary

The overall purpose of this research is to determine whether new macromolecular measures optimized for whole brain (gray matter and white matter) magnetic resonance imaging (MRI), predict neuro-cognitive impairment in multiple sclerosis (MS) patients.

Clinical Trial Description

MRI is a vital component of a MS work-up, providing noninvasive evidence of MS lesions, detecting active inflammatory lesions, and measuring brain atrophy to assess neurodegeneration. Recent years of MRI research have generated strong evidence of gray matter (GM) involvement in MS, resulting in the reclassification of MS as a whole-brain disease. Similar to white matter (WM), a primary target of MS pathology in GM is myelin, the protective sheath insulating the penetrating axons within GM and extending brain connectivity all the way to the neuronal bodies.

This aim of this research is to examine if the associations between imaging measures of GM disease and cognitive performance can establish GM-based imaging correlates predicting the disease course and accurately assessing treatment results.

This observational research will enroll adults diagnosed with MS both with and without cognitive impairment. Subjects will be asked to complete a single research visit that includes the administration of a MRI scan and a neuro-cognitive testing session. ;

Related Conditions & MeSH terms

• MS
• Multiple Sclerosis
• Sclerosis

• NCT number: NCT04415372
• Study type: Observational
• Source: University of Wisconsin, Madison
• Status: Enrolling by invitation
• Start date: November 19, 2021
• Completion date: April 2027